Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

September 23, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search